Classification, grading, staging and reporting of GU tumors have evolved significantly in recent years as molecular profiling has made a significant impact on tumor taxonomy and classification. Precision medicine and targeted therapies have emphasized the critical role of histopathological classification in prediction of prognosis and therapeutic response for cancer. These important changes are codified in the WHO Blue Book on Tumors of the Urinary System and Male Genital Organs. The 5th edition is eagerly anticipated in the spring of 2022 and is a complete revision of the 4th edition published in 2016. Expert faculty will guide attendees through the important changes and “new things” in the 5th edition WHO Blue Book in order to generate diagnoses and reports that meet the contemporary patient management needs.

Target Audience

Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives

Upon completion of this educational activity, learners will be able to:
- Recognize, correctly diagnose and classify new GU tumor types
- Correctly apply new and modified grading criteria for GU cancers
- Correctly apply new and modified staging criteria for GU cancers
- Learn new reporting requirements for GU tumors
- Understand the role of histomorphological classification in precision patient management

Items Included in the Purchase of this Course

- Prostate Pathology - Rajal Shah, MD
- Kidney Pathology - Ming Zhou, MD, PhD
- Bladder Pathology - Donna Hansel, MD, PhD
- Testicular Pathology - Sunny Kao, MD

Original release date: December 21, 2022
Access to this course expires on:  November 15, 2025